A key element of Congenia's strategy is to establish strategic collaborations.
Congenia has established research collaborations with a number of world-leading academic and industrial partners to:
  • facilitate a detailed understanding of the mode of action of mPTP and p66 inhibitors at the molecular, cellular and physiological levels in a variety of disease contexts
  • expedite the progression of its drug discovery programmes
Partnering and Licensing contact

To discuss any form of potential collaboration opportunity with Congenia, please contact
Dr. Federica Draghi or find us at one of the upcoming business conference:

Tel: +39 02 36515110